Business Standard

Sunday, December 22, 2024 | 11:27 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Saudi to soon begin Phase III clinical trial of CanSino's Covid-19 vaccine

The vaccine uses a harmless cold virus known as adenovirus type-5 (Ad5) to carry genetic material from the coronavirus into the body

vaccine, pharma, coronavirus, medicine, drugs, medical research, covid, lab
Premium

Saudi Arabia plans to test the vaccine alongside a placebo on 5,000 volunteers

Press Trust of India New Delhi
Saudi Arabia will soon begin Phase III clinical trials on around 5,000 people for a Covid-19 vaccine developed by China's CanSino Biologics Inc, a Saudi health ministry spokesman said on Sunday.
 
Last month, CanSino's co-founder said the company was in talks with Russia, Brazil, Chile and Saudi Arabia to launch a Phase III trial of the vaccine candidate, Ad5-nCOV.
 
The vaccine uses a harmless cold virus known as adenovirus type-5 (Ad5) to carry genetic material from the coronavirus into the body.

Researchers said last month

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in